Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Szubert

Showing results (21-30 of 46) with videos related to

Pageof 5
Sort By:
The Pediatric Infectious Disease Journal|February 24, 2026
Body Composition Changes in Children Living With HIV Initiated on Dolutegravir or Protease Inhibitors in the CHAPAS-4 TrialEva Natukunda, Alex J Szubert, Mutsa Bwakura-Dangarembizi, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|June 18, 2011
Gender disparities in the tumor genetics and clinical outcome of multiple myelomaKevin D Boyd, Fiona M Ross, Laura Chiecchio, et al.
AIDS (London, England)|April 23, 2019
Inflammatory biomarkers in HIV-infected children hospitalized for severe malnutrition in Uganda and ZimbabweAndrew J Prendergast, Chipo Berejena, Godfrey Pimundu, et al.
Haematologica|October 17, 2015
Minimal residual disease following autologous stem cell transplant in myeloma: impact on outcome is independent of induction regimenRuth M de Tute, Andy C Rawstron, Walter M Gregory, et al.
Plos Medicine|November 15, 2017
Virological response and resistance among HIV-infected children receiving long-term antiretroviral therapy without virological monitoring in Uganda and Zimbabwe: Observational analyses within the randomised ARROW trialAlexander J Szubert, Andrew J Prendergast, Moira J Spyer, et al.
The Journal of Infectious Diseases|May 19, 2016
Baseline Inflammatory Biomarkers Identify Subgroups of HIV-Infected African Children With Differing Responses to Antiretroviral TherapyAndrew J Prendergast, Alexander J Szubert, Chipo Berejena, et al.
AIDS (London, England)|August 29, 2025
Pharmacokinetics of lopinavir/ritonavir in second-line treatment of children living with HIV in the CHAPAS-4 trialAnne E M Kamphuis, Timo Kiezebrink, Hylke Waalewijn, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 8, 2018
Causes and Timing of Mortality and Morbidity Among Late Presenters Starting Antiretroviral Therapy in the REALITY TrialFrank A Post, Alexander J Szubert, Andrew J Prendergast, et al.
AIDS (London, England)|July 16, 2021
The impact of viraemia on inflammatory biomarkers and CD4+ cell subpopulations in HIV-infected children in sub-Saharan AfricaAndrew J Prendergast, Alexander J Szubert, Godfrey Pimundu, et al.
Leukemia|August 13, 2011
A novel prognostic model in myeloma based on co-segregating adverse FISH lesions and the ISS: analysis of patients treated in the MRC Myeloma IX trialK D Boyd, F M Ross, L Chiecchio, et al.
Pageof 5

Showing results (21-30 of 46) with videos related to

Sort By:
Pageof 5
The Pediatric Infectious Disease Journal|February 24, 2026
Body Composition Changes in Children Living With HIV Initiated on Dolutegravir or Protease Inhibitors in the CHAPAS-4 TrialEva Natukunda, Alex J Szubert, Mutsa Bwakura-Dangarembizi, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|June 18, 2011
Gender disparities in the tumor genetics and clinical outcome of multiple myelomaKevin D Boyd, Fiona M Ross, Laura Chiecchio, et al.
AIDS (London, England)|April 23, 2019
Inflammatory biomarkers in HIV-infected children hospitalized for severe malnutrition in Uganda and ZimbabweAndrew J Prendergast, Chipo Berejena, Godfrey Pimundu, et al.
Haematologica|October 17, 2015
Minimal residual disease following autologous stem cell transplant in myeloma: impact on outcome is independent of induction regimenRuth M de Tute, Andy C Rawstron, Walter M Gregory, et al.
Plos Medicine|November 15, 2017
Virological response and resistance among HIV-infected children receiving long-term antiretroviral therapy without virological monitoring in Uganda and Zimbabwe: Observational analyses within the randomised ARROW trialAlexander J Szubert, Andrew J Prendergast, Moira J Spyer, et al.
The Journal of Infectious Diseases|May 19, 2016
Baseline Inflammatory Biomarkers Identify Subgroups of HIV-Infected African Children With Differing Responses to Antiretroviral TherapyAndrew J Prendergast, Alexander J Szubert, Chipo Berejena, et al.
AIDS (London, England)|August 29, 2025
Pharmacokinetics of lopinavir/ritonavir in second-line treatment of children living with HIV in the CHAPAS-4 trialAnne E M Kamphuis, Timo Kiezebrink, Hylke Waalewijn, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 8, 2018
Causes and Timing of Mortality and Morbidity Among Late Presenters Starting Antiretroviral Therapy in the REALITY TrialFrank A Post, Alexander J Szubert, Andrew J Prendergast, et al.
AIDS (London, England)|July 16, 2021
The impact of viraemia on inflammatory biomarkers and CD4+ cell subpopulations in HIV-infected children in sub-Saharan AfricaAndrew J Prendergast, Alexander J Szubert, Godfrey Pimundu, et al.
Leukemia|August 13, 2011
A novel prognostic model in myeloma based on co-segregating adverse FISH lesions and the ISS: analysis of patients treated in the MRC Myeloma IX trialK D Boyd, F M Ross, L Chiecchio, et al.
Pageof 5